Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT6003 Injection Radioembolization in Previously Treated Hepatocellular Carcinoma
NCT07657273Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of TareSphere in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
TareSphere
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07657273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657273.